Clinical Trial

Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total Knee Arthroplasty.
Trial Details
NCT Number NCT06963320
Lead Sponsor Livzon Pharmaceutical Group Inc.
Conditions Circulatory Disease
Enrollment 320 participants
Start Date 2025-01-20
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-09